company background image
EPGN.F logo

Epigenomics OTCPK:EPGN.F Stock Report

Last Price

US$0.79

Market Cap

US$635.0k

7D

0%

1Y

n/a

Updated

22 Sep, 2024

Data

Company Financials

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Epigenomics AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for Epigenomics
Historical stock prices
Current Share Price€0.79
52 Week High€0.80
52 Week Low€0.50
Beta1.2
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Change-46.20%
5 Year Change-50.03%
Change since IPO-83.38%

Recent News & Updates

Recent updates

Shareholder Returns

EPGN.FUS BiotechsUS Market
7D0%-1.2%-4.1%
1Yn/a-5.6%6.6%

Return vs Industry: Insufficient data to determine how EPGN.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how EPGN.F performed against the US Market.

Price Volatility

Is EPGN.F's price volatile compared to industry and market?
EPGN.F volatility
EPGN.F Average Weekly Movementn/a
Biotechs Industry Average Movement10.8%
Market Average Movement6.4%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market3.4%

Stable Share Price: EPGN.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine EPGN.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19986Noel Dohenywww.epigenomics.com

Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company’s products also include Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA.

Epigenomics AG Fundamentals Summary

How do Epigenomics's earnings and revenue compare to its market cap?
EPGN.F fundamental statistics
Market capUS$635.02k
Earnings (TTM)US$3.31m
Revenue (TTM)US$152.07k

0.2x

P/E Ratio

4.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EPGN.F income statement (TTM)
Revenue€136.23k
Cost of Revenue€13.91k
Gross Profit€122.32k
Other Expenses-€2.84m
Earnings€2.96m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)3.39
Gross Margin89.79%
Net Profit Margin2,176.13%
Debt/Equity Ratio-136.9%

How did EPGN.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/09/22 16:54
End of Day Share Price 2024/06/25 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Epigenomics AG is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hans Bjorn BostromEdison Investment Research
Marietta Miemietzequinet Bank AG (ESN)
Simon ScholesFirst Berlin Equity Research GmbH